- What is Lasting Effect Consumer Pharma's primary focus?
- Lasting Effect Consumer Pharma develops pharmaceutical therapeutics utilizing a proprietary buccal extended-release drug delivery system.
- What is the core technology behind Lasting Effect Consumer Pharma's drug delivery system?
- The company's technology involves adhesive tablets designed to attach to the oral mucosa, allowing for continuous administration of active ingredients topically or systemically while bypassing the digestive tract.
- What are some key applications of Lasting Effect Consumer Pharma's platform?
- Key applications include saliva-stimulating treatments for dry mouth (xerostomia) and anti-bacterial formulations for gingivitis. The company also offers a non-invasive solution for late-stage Parkinson’s disease.
- When was Lasting Effect Consumer Pharma founded?
- Lasting Effect Consumer Pharma was founded in March 2020.
- How many employees does Lasting Effect Consumer Pharma have?
- Lasting Effect Consumer Pharma has 1-10 employees.
- What is the total amount of funding Lasting Effect Consumer Pharma has raised?
- Lasting Effect Consumer Pharma has raised a total of $1,850,000.
- Which investors participated in Lasting Effect Consumer Pharma's January 2023 funding round?
- In January 2023, Lasting Effect Consumer Pharma received funding from MaccabiDent and OurCrowd.
- What type of funding did Lasting Effect Consumer Pharma receive in January 2023 from the Israel Innovation Authority?
- In January 2023, Lasting Effect Consumer Pharma received an $850,000 grant from the Israel Innovation Authority.
- Who are the founders of Lasting Effect Consumer Pharma?
- The founders of Lasting Effect Consumer Pharma are David Tavor, Igal Pikovsky (CEO), and Eli Heldman (CTO).
